Two former high-ranking pharmaceutical executives are leading a new Cambridge, Mass., biotech that has received $58 million in venture capital to develop treatments for disorders related to the immune system.

Anthony J. Coyle, a former senior vice president at Pfizer (PFE), has been named chief executive, and Jo Viney, a former senior vice president at Biogen (BIIB), will become chief scientific officer of the newly founded Pandion Therapeutics, the company said Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy